In line with the ESC mission, newly presented content is made available to all for a limited time (4 months for ESC Congress, 3 months for other events). ESC Professional Members, Association Members (Ivory & above) benefit from year-round access to all the resources from their respective Association, and to all content from previous years. Fellows of the ESC (FESC), and Professionals in training or under 40 years old, who subscribed to a Young Combined Membership package benefit from access to all ESC 365 content from all events, all editions, all year long. Find out more about ESC Memberships here.
Sacubitril/Valsartan use in a real world experience: data from a large single-center population of heart failure patients with reduced ejection fraction
Authors : M Mapelli (Milan,IT), E Salvioni (Milan,IT), F De Martino (Milan,IT), I Mattavelli (Milan,IT), P Gugliandolo (Milan,IT), C Vignati (Milan,IT), A Magini (Milan,IT), S Rovai (Siena,IT), S Paolillo (Naples,IT), PG Agostoni (Milan,IT)
M Mapelli1
,
E Salvioni1
,
F De Martino1
,
I Mattavelli1
,
P Gugliandolo1
,
C Vignati1
,
A Magini1
,
S Rovai2
,
S Paolillo3
,
PG Agostoni1
,
1Cardiology Center Monzino IRCCS - Milan - Italy
,
2University of Siena - Siena - Italy
,
3Federico II University Hospital - Naples - Italy
,
Topic(s): Chronic Heart Failure: Pharmacotherapy
Background: Sacubitril/Valsartan has emerged as a novel therapy in the treatment of heart failure (HF) with reduced ejection fraction (HFrEF), showing a lower cardiovascular mortality and HF hospitalization rates compared to standard therapy. Although the recent widespread use of Sacubitril/Valsartan, real life data are still lacking. Methods: We performed a retrospective analysis of 201 monocentric patients with HFrEF, who started Sacubitril/Valsartan between September 2016 and December 2018 and followed at our HF ambulatory.We collected demographic data, clinical history with ongoing medications, baseline clinical characteristics and follow up (i.e. period of treatment until last contact with the hospital or by telephone call) about tolerated dose of Sacubitril/Valsartan, interruption of treatment, hospitalization for HF, deaths. Results: Baseline characteristics of our population and of PARADIGM trial are presented in Tab. 1 and Fig.1A. One hundred and five patients also performed a cardiopulmonary exercise test before starting treatment, showing a mean peak VO2 of 14.9 ± 4.7 ml/min/kg (60 ± 17 % of predicted), with VE/VCO2 slope of 34.3±8.2, VO2/work of 9.4±1.5. During follow up (268 ±185 days) 36 patients had hospitalization for HF, while 20 patients interrupted treatment with Sacubitril/Valsartan (7 hypotension, 5 renal insufficiency, 1 angioedema, 7 not known/patient decision) and 9 deceased. Dose administered at baseline and at the end of follow-up is reported in Fig. 1B. Conclusions: Compared to PARADIGM trial, our real-life population has similar characteristics and HF gravity. For clinical reasons during follow up only 31% reached the maximum dose. In future more studies are needed to analyze the prognostic impact of low vs. higher doses.
Mean
n(%)
PARADIGM trial
Mean
n (%)
Age (years)
67.2
±
10.8
63.8
±
11.5
Female sex
42 (21%)
879 (21%)
White
198 (99%)
2781 (66%)
BMI (kg/m2)
26.1
±
4.1
28.1
±
5.5
SBP (mmHg)
116.8
±
11.8
122
±
15
NYHA II
130 (65%)
2998 (72%)
NYHA III
71 (35%)
969 (23%)
Ischemic Etiology
109 (54%)
2506 (60%)
ICD
84 (42%)
623 (15%)
CRT
57 (28%)
292 (7%)
Baseline charachteristics compared to PARADIGM trial
In line with the ESC mission, newly presented content is made available to all for a limited time (4 months for ESC Congress, 3 months for other events). ESC Professional Members, Association Members (Ivory & above) benefit from year-round access to all the resources from their respective Association, and to all content from previous years. Fellows of the ESC (FESC), and Professionals in training or under 40 years old, who subscribed to a Young Combined Membership package benefit from access to all ESC 365 content from all events, all editions, all year long. Find out more about ESC Memberships here.